Pancreatic cancer genetic testing: BRCA and other results that may change treatment

Separate inherited results from tumor findings

Germline testing uses a sample such as blood or saliva to look for inherited changes. Tumor profiling examines cancer tissue or tumor DNA to identify alterations in the cancer. One does not always replace the other.

A BRCA result from tumor testing may lead to germline confirmation because it can represent either an inherited or a tumor-only change. Keep the sample type and the full report visible when asking for a treatment opinion. The word positive is not enough to establish what the result means.

Sources and references: [1]

Ask about testing early enough to affect a decision

Testing is most useful when the team knows what decision the result could change. It may affect the chemotherapy discussion, a maintenance plan or eligibility for a trial. Existing tissue can sometimes be used, while another sample may be needed if the original material is insufficient.

Ask which tests are already complete and when the remaining results are expected. Urgent treatment of jaundice, infection or severe symptoms should continue while testing is organized. A clear testing plan prevents repeated biopsies or duplicate reports that do not answer a new question.

Sources and references: [2] [3]

Why BRCA matters for platinum chemotherapy

BRCA1 and BRCA2 help repair damaged DNA. Harmful variants can make a pancreatic tumor more sensitive to platinum-based treatment. This finding therefore belongs in the initial treatment discussion, alongside fitness and organ function.

The actual regimen still needs clinical selection. Ask whether the result is pathogenic or likely pathogenic and whether it is germline. A variant of uncertain significance has a different meaning and should not be treated as a proven target simply because it appears in the BRCA section of a report.

Sources and references: [2] [1]

Understand the specific olaparib pathway

Maintenance olaparib can be considered for metastatic pancreatic adenocarcinoma with a harmful germline BRCA1 or BRCA2 variant after disease has not progressed during at least 16 weeks of first-line platinum-based chemotherapy. It is a maintenance strategy following disease control.

In the POLO trial, this approach delayed progression compared with placebo; the study did not establish a statistically significant overall survival advantage. Ask how maintenance compares with other reasonable next steps for you, including ongoing chemotherapy and the side effects already accumulating.

Sources and references: [2]

Other biomarkers may lead to targeted or immune treatment discussions

Tumor profiling can identify findings relevant to targeted treatment or immunotherapy, including MSI-high or mismatch repair-deficient disease. The options have also changed: in August 2026, the U.S. FDA approved the RAS inhibitor daraxonrasib for adults with metastatic pancreatic adenocarcinoma after at least one systemic therapy, or when they are not candidates for multiagent systemic therapy.

That U.S. indication is distinct from establishing a prescribing pathway in China. Ask the oncologist which result supports each proposed medicine, what the current local indication is and whether access is ordinary treatment or research. Rash, diarrhea and mouth inflammation are among daraxonrasib's common adverse effects; a targeted tablet still needs a specific monitoring plan.

Sources and references: [3] [5]

A negative or uncertain result still needs explanation

A negative result means the test did not identify the relevant alteration within its scope. It does not mean every possible marker has been assessed. Low tumor content, limited tissue or the type of assay can affect what a report can answer.

For a VUS, ask whether reclassification updates are available and who will receive them. Avoid treating an uncertain finding as a reason to make major family-risk decisions. Genetic counseling can connect the laboratory language with your personal and family history.

Sources and references: [1]

Keep the family discussion distinct from immediate treatment

A confirmed harmful inherited variant may have implications for relatives. Counseling can explain who might consider testing and which confirmed family variant is relevant. A tumor-only finding does not establish that a family member carries it.

For the patient's immediate care, keep the treatment question clear: does this result change the next chemotherapy, support a maintenance option or identify a trial? Separating these questions helps the consultation cover both treatment and family concerns without confusing their purposes.

Sources and references: [1] [2]

Send complete reports for a Shanghai treatment review

A pancreatic cancer inquiry to Fudan University Shanghai Cancer Center can clarify the appropriate service for bringing molecular findings into the treatment plan. The genetic report should travel with pathology and the clinical timeline.

EastMedGo can help assemble the records and frame the question for the receiving team. Include the sample type, exact variant report, chemotherapy names and response scans. We can clarify whether further materials are requested and help coordinate consultation arrangements before a trip is planned.

Sources and references: [4]

Common questions